Dimensional Fund Advisors LP grew its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 52.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,680,535 shares of the biopharmaceutical company's stock after buying an additional 580,787 shares during the quarter. Dimensional Fund Advisors LP owned 0.29% of Royalty Pharma worth $42,866,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Franklin Resources Inc. grew its position in shares of Royalty Pharma by 5.0% during the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock worth $40,705,000 after purchasing an additional 70,130 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock valued at $79,888,000 after buying an additional 130,025 shares in the last quarter. Pallas Capital Advisors LLC bought a new position in shares of Royalty Pharma in the 4th quarter valued at about $2,355,000. Jupiter Asset Management Ltd. purchased a new position in Royalty Pharma in the fourth quarter worth about $4,950,000. Finally, Allspring Global Investments Holdings LLC increased its stake in Royalty Pharma by 303.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company's stock worth $13,926,000 after acquiring an additional 406,123 shares during the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.
Royalty Pharma Stock Performance
Shares of NASDAQ RPRX traded up $0.11 during midday trading on Friday, reaching $33.21. The company had a trading volume of 1,105,707 shares, compared to its average volume of 3,296,997. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The business's 50-day simple moving average is $32.39 and its 200 day simple moving average is $29.72. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The stock has a market cap of $19.14 billion, a P/E ratio of 22.90, a P/E/G ratio of 2.31 and a beta of 0.49.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.
Royalty Pharma Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.65%. Royalty Pharma's dividend payout ratio is presently 60.69%.
Wall Street Analysts Forecast Growth
Separately, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Royalty Pharma currently has a consensus rating of "Buy" and an average price target of $42.50.
Get Our Latest Research Report on RPRX
About Royalty Pharma
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Stories
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
